Significant Non-Dilutive Funding For Preclinical HIE Studies
Filed with ASX · · 2 pages · English
Perth, Australia; 30 March, 2023 - Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel neuroprotective therapeutics, is pleased to announce the receipt of non-dilutive cash funding from the Stan Perron Charitable Foundation (SPCF) to the Perron Institute for Neurological and Translational Sciences (The Perron Institute) to progress precl
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- Interim Phase 1 Safety Report Confirms Safety of ARG-007
- Non-Dilutive Funding Received to Progress Alzheimers Studies
- Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers
- Argenica Awarded $1.2m CRC-P Grant for TBI Project
- Successful Completion of Phase 1 Clinical Trial Dosing
Later from Argenica Therapeutics
- Latest Preclinical HIE Study Results
- Final Phase1 Clinical Trial Report
- Argenica Successfully Completes $4.0m Placement
- ARG-007 Protects Brain Cells in Moderate TBI Model
- ARG-007 Phase 2 Clinical Trial Update
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics